
1. Lancet. 2021 Nov 20;398(10314):1872-1873. doi: 10.1016/S0140-6736(21)02324-2.

Long-term effects on survivors with COVID-19 - Authors' reply.

Huang L(1), Gu X(2), Cao B(3).

Author information: 
(1)Department of Pulmonary and Critical Care Medicine, Capital Medical
University, Beijing, China; Department of Pulmonary and Critical Care Medicine,
National Centre for Respiratory Medicine, Centre of Respiratory Medicine,
National Clinical Research Centre for Respiratory Diseases, China-Japan
Friendship Hospital, Beijing 100029, China.
(2)Department of Pulmonary and Critical Care Medicine, National Centre for
Respiratory Medicine, Centre of Respiratory Medicine, National Clinical Research 
Centre for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029,
China; Institute of Clinical Medical Sciences, China-Japan Friendship Hospital,
Beijing 100029, China.
(3)Department of Pulmonary and Critical Care Medicine, National Centre for
Respiratory Medicine, Centre of Respiratory Medicine, National Clinical Research 
Centre for Respiratory Diseases, China-Japan Friendship Hospital, Beijing 100029,
China; Institute of Clinical Medical Sciences, China-Japan Friendship Hospital,
Beijing 100029, China; Institute of Respiratory Medicine, Chinese Academy of
Medical Science, Beijing, China; Tsinghua University-Peking University Joint
Centre for Life Sciences, Beijing, China. Electronic address: caobin_ben@163.com.

Comment on
    Lancet. 2021 Nov 20;398(10314):1871-1872.
    Lancet. 2021 Nov 20;398(10314):1872.

DOI: 10.1016/S0140-6736(21)02324-2 
PMCID: PMC8601684
PMID: 34801102  [Indexed for MEDLINE]

Conflict of interest statement: We declare funding by the Chinese Academy of
Medical Sciences Innovation Fund for Medical Sciences (CIFMS 2018-I2M-1–003 and
2020-I2M-CoV19–005), the National Natural Science Foundation of China
(82041011/H0104), the National Key Research and Development Programme of China
(2018YFC1200102), and Major Projects of National Science and Technology on New
Drug Creation and Development of Pulmonary Tuberculosis (2020ZX09201001). This
Correspondence was also supported by the China Evergrande Group, Jack Ma
Foundation, Sino Biopharmaceutical, Ping An Insurance Group, and New Sunshine
Charity Foundation.

